B Acute Lymphoblastic Leukemia - inotuzumab ozogamicin - CD58 expression

Association details:

Biomarker:	CD58 expression
Cancer:	B Acute Lymphoblastic Leukemia
Drug:	Besponsa (inotuzumab ozogamicin) (DNA replication inhibitor, CD22-targeted antibody-drug conjugate)
Direction:	Sensitive

Evidence:

Evidence Level:

Sensitive: C3 – Early Trials

Source:

ASH 2023

Title:

Analysis of CD58 As a Predictive Marker of Morphologic Response to Inotuzumab Ozogamicin in Patients with B-Cell Acute Lymphoblastic Leukemia

Published date:

11/02/2023

Excerpt:

In this study, we evaluated the correlation of CD58 expression with achievement of morphologic Complete Remission (CR) or Complete Remission with incomplete blood count recovery (CRi) after treatment with INO….Median Overall Survival (OS) was 21.5 months (range, 1-58) with a median leukemia-free survival (LFS) of 13.5 months (range, 1-52). Response rates after INO were high, including 28 patients (82.4%) achieving CR, 30 patients (88.2%) achieving CR/CRi, and 27 patients (79.4%) achieving Measurable Residual Disease (MRD) negativity.

DOI:

https://doi.org/10.1182/blood-2023-180883